Who is eligible for clinical trial NCT07541287?

Participants must meet protocol criteria for IgA Nephropathy. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT07541287 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-18

A Study of JADE101 in Participants With Immunoglobulin A Nephropathy (NCT07541287)

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Jade Biosciences, Inc.

🩺 Plain-English Summary (8th-Grade Level)

This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient population.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (13 items).

Location: Jade Clinical Site — Chula Vista, California

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Male or female participants 18-60 years of age, inclusive, and of local legal consenting age at the time of signing the informed consent
eGFR ≥ 30 mL/min/1.73 m2
Biopsy-confirmed primary IgAN
Receiving stable and maximally tolerated doses of either ACEi or ARB as per standard of care (SoC) and applicable guidelines for at least 12 weeks prior to the initial screening visit, with no intention to alter the dose or discontinue treatment, unless medically necessary
UPCR ≥ 0.75 g/g
Willing to provide written informed consent
Willing and able to comply with scheduled study visits, treatment plans, laboratory tests, and other study procedures
Willing and able to comply with contraceptive and lifestyle requirements

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Secondary forms of IgAN
Known or suspected coexisting Chronic Kidney Disease (CKD) other than IgAN
Known or suspected rapidly progressive glomerulonephritis (RPGN)
Evidence of pathological findings in the kidney biopsy in addition to IgAN (eg, minimal change disease, diabetic kidney disease, membranous nephropathy, focal segmental glomerulosclerosis, or lupus nephritis); hypertensive vascular changes are acceptable
Known or suspected primary or secondary immunodeficiency disorder
Evidence of tuberculosis infection at screening
Any chronic infectious disease
Any acute infectious disease at time of screening
Received bone marrow, hematologic stem cell transplantation, or a solid organ transplant, including kidney
Known or suspected alcohol or drug abuse
Any clinically significant and/or unstable or uncontrolled medical condition as assessed by the investigator

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗

A Study of JADE101 in Participants With Immunoglobulin A Nephropathy (NCT07541287)

🩺 Plain-English Summary (8th-Grade Level)

📋 "Do I Qualify?" — 1-Minute Self Screener

Usually NOT eligible if any of the following apply:

📍 All Participating Trial Locations (15 Sites)

💰 Cost, Insurance & Patient Rights